AEZS-132, a new orally bioavailable PI3K/Erk inhibitor with antitumor effects

被引：0
|
作者：
Seipelt, I. [1 ]
Gerlach, M. [2 ]
Baasner, S. [1 ]
Blumenstein, L. [1 ]
Mueller, G. [2 ]
Aicher, B. [1 ]
Engel, J. [3 ]
Guenther, E. [4 ]
Teifel, M. [1 ]
机构：
[1] Aeterna Zentaris GmbH, Preclin Dev, Frankfurt, Germany
[2] Aeterna Zentaris GmbH, Med Chem, Frankfurt, Germany
[3] Aeterna Zentaris GmbH, Management Board, Frankfurt, Germany
[4] Aeterna Zentaris GmbH, Alliance Management, Frankfurt, Germany
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)71902-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [31] Identification of GSK2636771, a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta (PI3Kα) for the treatment of PTEN deficient tumors
    Rivero, Ralph A.
    Hardwicke, Mary Ann
    CANCER RESEARCH, 2012, 72
  • [32] Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
    Till, Kathleen J.
    Abdullah, Mariah
    Alnassfan, Tahera
    Janet, Gallardo Zapata
    Marks, Thomas
    Coma, Silvia
    Weaver, David T.
    Pachter, Jonathan A.
    Pettitt, Andrew R.
    Slupsky, Joseph R.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [33] Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
    Kathleen J. Till
    Mariah Abdullah
    Tahera Alnassfan
    Gallardo Zapata Janet
    Thomas Marks
    Silvia Coma
    David T. Weaver
    Jonathan A. Pachter
    Andrew R. Pettitt
    Joseph R. Slupsky
    Scientific Reports, 13
  • [34] Pi3kδ Inhibitor Pulmonary Toxicity
    Bender, M. T.
    Sanso, L. M.
    Narula, N.
    Harvey, B-G.
    Kaner, R. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [35] Antitumor Activity of Tipifarnib and PI3K Pathway Inhibitor in HRAS-associated HNSCC
    Smith, A.
    Chan, S.
    McCloskey, A.
    Vora, H.
    Burrows, F.
    Malik, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E48 - E48
  • [36] VS-5584, a PI3K/mTOR dual inhibitor, exerts antitumor effects on neuroblastomas in vitro and in vivo
    Chen, Yun
    Tsai, Huang-Wen
    Tsai, Ya-Hui
    Tseng, Sheng-Hong
    JOURNAL OF PEDIATRIC SURGERY, 2021, 56 (08) : 1441 - 1448
  • [37] In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
    Alia Albawardi
    Muna Al Ayyan
    Mohamed Al Bashir
    Abdul-Kader Souid
    Saeeda Almarzooqi
    Cancer Cell International, 14
  • [38] In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
    Albawardi, Alia
    Al Ayyan, Muna
    Al Bashir, Mohamed
    Souid, Abdul-Kader
    Almarzooqi, Saeeda
    CANCER CELL INTERNATIONAL, 2014, 14
  • [39] INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer
    Jessen, Katayoun A.
    Kessler, Linda
    Kucharski, Jeff
    Guo, Xin
    Staunton, Jocelyn
    Elia, Marikka
    Janes, Matthew
    Lan, Lucy
    Wang, Shunyou
    Stewart, Josh
    Darjania, Levan
    Li, Liansheng
    Chan, Katrina
    Martin, Michael
    Ren, Pingda
    Fruman, David
    Rommel, Christian
    Liu, Yi
    CANCER RESEARCH, 2011, 71
  • [40] The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling
    Schwartz, Sarit
    Carver, Brett S.
    Wongvipat, John
    Rodrik-Outmezguine, Vanessa
    Stanchina, Elisa D.
    Trigwell, Cath
    Barry, Simon
    Baselga, Jose
    Chandarlapaty, Sarat
    Scher, Howard I.
    Sawyers, Charles L.
    Rosen, Neal
    CANCER RESEARCH, 2014, 74 (19)
12345